Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Neurocognitive Effects and Tolerability of Efavirenz in Aging HIV-infected Individuals ("SHAC Neuro Study")

Authors not listed

Stanford University · 2013

Abstract

Investigators hypothesize that older HIV-infected individuals (i.e., \>50 years old) on efavirenz (EFV)-containing antiretroviral therapy (ART) will have significantly worse neurocognitive function than older individuals on non-EFV-containing ART.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-10-08 MST

Cite this

APA
Anonymous. (2013). Neurocognitive Effects and Tolerability of Efavirenz in Aging HIV-infected Individuals ("SHAC Neuro Study"). <em>Stanford University</em>. https://clinicaltrials.gov/study/NCT01985399
Vancouver
Anonymous. Neurocognitive Effects and Tolerability of Efavirenz in Aging HIV-infected Individuals ("SHAC Neuro Study"). Stanford University. 2013.
BibTeX
@misc{anon2013Neuroc, title = {Neurocognitive Effects and Tolerability of Efavirenz in Aging HIV-infected Individuals ("SHAC Neuro Study")}, author = {Anonymous}, journal = {Stanford University}, year = {2013}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings